$COO (The Cooper Companies Inc.)

$COO {{ '2016-06-03T07:47:58+0000' | timeago}} • Webcast

$COO expects effective tax rate to be about 8% and share count is expected to be about 49.1MM shares in FY16. CapEx is expected to be around $200MM, as company finishes paying for equipment ordered over the prior year. Adjusted free cash flow is expected to be around $300MM.

$COO {{ '2017-07-06T20:48:37+0000' | timeago}} • Announcement

$COO has declared a semi-annual dividend of 3 cents per share, payable on August 7, 2017, to stockholders of record on July 21, 2017.

$COO {{ '2017-06-02T11:34:54+0000' | timeago}} • Webcast

$COO stated that on the consumer purchasing trend, the company is seeing solid trends. The biggest driver in the marketplace continues to be the trading up, which means taking the existing consumer base and moving it from the two-week modality into primarily the one-day modality.

$COO {{ '2017-06-02T11:11:33+0000' | timeago}} • Webcast

$COO expects 3Q17 EPS to be slightly lower than 4Q17 due to lower sequential GM at CooperVision. This 3Q17 reduction is due to inventory turns every six months and production level declines in Dec. and Jan. due to annual manufacturing shutdowns to upgrade and retool $COO's plants.

$COO {{ '2017-06-02T11:02:51+0000' | timeago}} • Webcast

$COO's operating expenses grew 8.8% in 2Q17, slightly above the reported revenue growth of 8%. This was driven by investments such as additional sales personnel, along with expenses from acquisition. Operating income growth however was strong, up 18.9%, driven by gross margin improvements. Operating margins grew 2.5% YoY to 26.8%.

$COO {{ '2017-06-02T10:51:59+0000' | timeago}} • Webcast

$COO commented that in the contact lens market overall, the company grew its share two times the market or 10% against the market growth of 5% in calendar first quarter. Geographically, $COO grew 8% in the Americas, 10% in EMEA and 16% in Asia-Pacific.

$COO {{ '2017-06-01T20:38:07+0000' | timeago}} • Announcement

$COO lifted its FY17 total revenue outlook to $2.110-2.135Bil from $2.09-2.13Bil and its non-GAAP EPS guidance to $9.50-9.65 from $9.10-9.30. The company also raised its FY17 CooperVision revenue estimate to $1.645-1.665Bil from $1.62-1.65Bil, while lowering its CooperSurgical revenue forecast to $465-470MM from $470-480MM.

$COO {{ '2017-06-01T20:37:42+0000' | timeago}} • Announcement

$COO reported a jump in 2Q17 earnings driven by higher sales as well as favorable currency and product mix within CooperVision led by Biofinity. Net income rose to $104.9MM or $2.12 per share from $74.1MM or $1.52 per share last year. Net sales grew to $522.4MM from $483.8MM. Non-GAAP EPS increased to $2.50 from $2.05.

$COO {{ '2017-03-21T20:58:25+0000' | timeago}} • Announcement

$COO's Board of Directors has approved a $500MM increase in the company's share repurchase program. The share repurchase program now totals $1Bil and has approximately $618.5MM of remaining availability with no expiration date.

$COO {{ '2017-03-02T21:42:24+0000' | timeago}} • Announcement

$COO said that during 1Q17, CooperVision segment continued gaining market share driven by growth in Biofinity and daily silicone hydrogel products while CooperSurgical segment continued its growth driven by fertility.

$COO {{ '2017-03-02T21:38:18+0000' | timeago}} • Announcement

For FY17, $COO expects total revenue in the range of $2.09-2.13Bil, CVI revenue in the range of $1.62-1.65Bil and CSI revenue in the range of $470-480MM. On a non-GAAP basis, diluted EPS for FY17 is expected in the range of $9.10-9.30.

$COO {{ '2017-03-02T21:32:56+0000' | timeago}} • Announcement

Medical device company $COO reported an increased 1Q17 earnings, driven by higher sales and strong growth in the CooperSurgical and CooperVision segments. Net income rose 47.58% to $75.8MM or $1.53 per share from $51.36MM or $1.05 per share in 1Q16. Revenue for the quarter rose 10.99% to $499.1MM. On an adjusted basis, $COO earned $1.93 per share.

$COO {{ '2017-01-06T14:07:18+0000' | timeago}} • Announcement

$COO has declared a semi-annual dividend of $0.03 per share, payable on February 9, 2017, to stockholders of record on January 23, 2017.

$COO {{ '2016-12-09T12:01:44+0000' | timeago}} • Webcast

$COO said that on the 1-day silicone hydrogel growth expectation for 2017, the company doesn't expect to sustain the 50% that it saw in 2016. On the FX assumptions of major currencies in 2017, $COO stated it expects pretty much today's rates.

$COO {{ '2016-12-09T11:25:02+0000' | timeago}} • Webcast

$COO stated that for FY17, the company expects gross margins to improve to around 64.5%, while operating margin is expected to improve to 25%. On the interest expense side, $COO expects it to be around $28MM for FY17, which includes the additional debt from the Wallace acquisition along with an assumption of 125 BP rate increase.

$COO {{ '2016-12-09T11:05:33+0000' | timeago}} • Webcast

Geographically, $COO said its EMEA region posted a strong quarter in 4Q16, up 12% in constant currency. Growth was driven by Biofinity and 1-day silicone hydrogel franchise. Asia-Pacific region also had a strong quarter, up 13% in constant currency. In Japan, $COO added that its MyDay, Sphere, and Toric launch is progressing well.

$COO {{ '2016-12-09T11:02:16+0000' | timeago}} • Webcast

$COO's CooperVision segment posted strong results in all key areas of its business in 4Q16, resulting in 10% as reported & 11% constant currency revenue growth. This is the fastest CooperVision has grown in 11 qtrs. CooperSurgical also had another strong qtr. posting revenue growth of 20%, while Fertility was the highlight posting a growth of 74%.

$COO {{ '2016-12-08T22:31:18+0000' | timeago}} • Infographic

$COO The Cooper Companies Earnings AlphaGraph: Q4 2016 Highlights

$COO {{ '2016-12-08T21:40:55+0000' | timeago}} • Announcement

$COO expects FY17 non-GAAP EPS in the range of $9.00-9.30 and 1Q17 non-GAAP EPS in the range of $1.78-1.88. The non-GAAP EPS guidance excludes amortization of intangible assets and other costs including integration expenses which the company may incur as part of its continuing operations.

$COO {{ '2016-12-08T21:38:07+0000' | timeago}} • Announcement

For FY17, $COO expects total revenue in the range of $2.09-2.13Bil, CVI revenue is expected to be in the range of $1.62-1.65Bil and CSI revenue in the range of $470-480MM. For 1Q17, $COO expects total revenue in the range of $494-508MM, CVI revenue in the range of $383-393MM and CSI revenue in the range of $111-115MM.

$COO {{ '2016-12-08T21:34:41+0000' | timeago}} • Announcement

Medical device company $COO posted higher 4Q16 earnings, helped by higher sales and strong growth in the CooperSurgical segment. The company's net income rose 64.96% to $60.50MM or $1.23 per share from $36.68MM or $0.75 per share a year ago. Revenue for the quarter rose 13.85% to $518.65MM. Excluding items, $COO earned $2.28 per share.

Recent Transcripts

ISRG (Intuitive Surgical, Inc.)
Thursday, July 20 2017 - 8:30pm
ABT (Abbott Laboratories)
Thursday, July 20 2017 - 1:00pm
NVS (Novartis AG)
Tuesday, July 18 2017 - 12:00pm
COO (The Cooper Companies Inc.)
Thursday, June 1 2017 - 9:00pm
MDT (Medtronic plc)
Thursday, May 25 2017 - 12:00pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
ENDP (Endo International plc)
Tuesday, May 9 2017 - 12:30pm
XRAY (DENTSPLY International Inc.)
Tuesday, May 9 2017 - 12:30pm
MTD (Mettler-Toledo International Inc.)
Thursday, May 4 2017 - 9:00pm
INCY (Incyte Corporation)
Thursday, May 4 2017 - 2:00pm
MTD (Mettler-Toledo International Inc.)
Thursday, May 4 2017 - 12:00pm
STAA (STAAR Surgical Company)
Wednesday, May 3 2017 - 8:30pm
MASI (Masimo Corporation)
Wednesday, May 3 2017 - 8:30pm
KTWO (K2M Group Holdings, Inc.)
Tuesday, May 2 2017 - 9:00pm
IDXX (IDEXX Laboratories, Inc.)
Friday, April 28 2017 - 12:30pm
HRC (Hill-Rom Holdings, Inc.)
Friday, April 28 2017 - 12:30pm
IART (Integra LifeSciences Holdings Corporation)
Wednesday, April 26 2017 - 12:30pm
MMM (3M Company)
Tuesday, April 25 2017 - 1:00pm
LH (Laboratory Corp. of America Holdings)
Tuesday, April 25 2017 - 1:00pm
LLY (Eli Lilly and Company)
Tuesday, April 25 2017 - 1:00pm

AlphaGraphics you may like